Paragon 28, INC

Paragon 28, Inc. has completed its merger with a subsidiary of Zimmer Biomet, resulting in the company becoming a wholly-owned subsidiary and the delisting of its common stock from the New York Stock Exchange.

Paragon 28, Inc. announces that its stockholders have approved the merger agreement with Zimmer, Inc., a wholly-owned subsidiary of Zimmer Biomet Holdings, Inc., at a special meeting held on April 17, 2025.

Paragon 28 updates its proxy statement with supplemental disclosures to address stockholder lawsuits and demand letters related to its pending merger with Zimmer Biomet.

Paragon 28 announces the expiration of the HSR Act waiting period, a significant step towards its acquisition by Zimmer Biomet.

Zimmer Biomet will acquire Paragon 28 for $13.00 per share in cash plus a contingent value right (CVR) that could add up to $1.00 per share, valuing the company at approximately $1.3 billion.

Zimmer Biomet has agreed to acquire Paragon 28 for $1.2 billion, including a contingent value right, to expand its presence in the high-growth foot and ankle orthopedic segment.

Paragon 28, a medical device company focused on foot and ankle orthopedics, announced an 18% increase in revenue for the third quarter of 2024, but also reported increased net losses and identified material weaknesses in internal controls.

Paragon 28, a medical device company focused on foot and ankle orthopedics, announced an 18% increase in revenue for the second quarter of 2024, although operating expenses also rose.

Paragon 28 has restated its first quarter 2024 financial statements due to material accounting errors related to inventory valuation.

Paragon 28, a medical device company focused on foot and ankle orthopedics, announced a 17% increase in net revenue for the first quarter of 2024, driven by new product launches and sales force expansion.

Paragon 28's 2024 10-K filing highlights a pending merger with Zimmer, Inc., alongside financial results and operational strategies.

Paragon 28 has restated its financial statements for fiscal year 2023 and interim periods due to material accounting errors related to inventory valuation and has identified material weaknesses in its internal controls.

Paragon 28, Inc.'s 10-K filing details the company's capital stock structure, anti-takeover provisions, and reports a 19% increase in revenue for 2023.

Robert S. McCormack, General Counsel and Corporate Secretary of Paragon 28, Inc., reports the disposition of common stock and performance stock units due to the merger with Zimmer Biomet Holdings, Inc.

Meghan Scanlon, a director of Paragon 28, Inc., reported the disposal of 42,113 shares of common stock due to the merger with Zimmer Biomet Holdings, Inc.

Thomas Schnettler, a director at Paragon 28, reports the disposal of common stock due to the merger with Zimmer Biomet, receiving cash and contingent value rights.

Stephen Oesterle, a director of Paragon 28, reports the disposition of common stock and stock options due to the merger with Zimmer Biomet Holdings, Inc.

Director B. Kristine Johnson reports the disposal of Paragon 28 shares following the company's merger with Zimmer Biomet, receiving cash and contingent value rights in exchange.

Matthew Jarboe, Chief Commercial Officer of Paragon 28, reports the disposition of common stock, performance stock units, and stock options due to the merger with Zimmer Biomet Holdings, Inc.

Zimmer Biomet (ZB) and Paragon 28 have entered into a definitive agreement for ZB to acquire Paragon 28, aiming to expand ZB's presence in the foot and ankle segment.

Paragon 28 announces its acquisition by Zimmer Biomet, aiming to enhance its mission to improve surgical outcomes in the foot and ankle market.

Paragon 28 urges shareholders to review proxy statements related to a proposed transaction, highlighting potential risks and benefits while navigating regulatory approvals.

Paragon 28, a foot and ankle care company, has entered into a definitive agreement to be acquired by Zimmer Biomet, a global medical technology leader.

Zimmer Biomet will acquire Paragon 28 for $13.00 per share in cash plus a contingent value right (CVR) payment, potentially reaching a total enterprise value of approximately $1.3 billion.

Zimmer Biomet will acquire Paragon 28 for $13.00 per share in cash, plus a contingent value right, to expand its presence in the foot and ankle orthopedic segment.